|
**Overview**: Microalbumin 24-Hour Urine Panel**Introduction**: The Microalbumin 24-Hour Urine Panel is a diagnostic tool designed to assess kidney damage using timed urine collection. In India, 24-hour urinary albumin excretion remains gold standard for quantifying proteinuria/microalbuminuria in diabetic/hypertensive nephropathy, with >30 mg/24h indicating early damage and progression risk. High morbidity from under-utilization in rural/low-SES patients with diabetes or hypertension, limited lab support for timed collections, delayed intensified renoprotection leading to advanced CKD or ESRD. Per nephrology practices aligned with ICMR, RSSDI, and Indian Society of Nephrology guidelines, the test employs spectrophotometry for microalbumin and total volume over 1-2 days with high accuracy, valuable for precise albumin excretion rate (AER) measurement. This diagnostic falls under renal screening and targets patients with borderline random ACR or high-risk nephropathy, addressing accurate detection to guide ACEi dose escalation or SGLT2 inhibitors. With elevated morbidity due to underdiagnosis, the test supports public health efforts by enabling quantitative kidney damage assessment and reducing progression burden. Its 24-hour urine-based approach ensures reliable total excretion quantification.**Other Names**: Microalb 24H Pnl.**FDA Status**: FDA approved, CLIA certified for biochemistry, compliant with 2025 standards.**Historical Milestone**: 24-hour urine albumin standard; in India, used in specialized nephrology.**Purpose**: The test assesses 2 parameters including microalbumin to guide kidney damage assessment, quantify AER, inform therapy intensification.**Test Parameters**: 1. Microalbumin, 2. Total Volume.**Pretest Condition**: No fasting required; patients should collect complete 24-hour urine.**Specimen**: 10 mL aliquot from 24-hour urine in 1 sterile container, transported within specified times to maintain sample viability.**Sample Stability at Room Temperature**: 24 hours with proper handling to preserve analyte integrity, ensuring reliable test performance.**Sample Stability at Refrigeration**: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.**Sample Stability at Frozen**: 6 months at -20 degrees Celsius, allowing long-term storage for retesting, though freezing may affect some analytes.**Medical History**: Patients should provide details on diabetes control, BP, proteinuria history.**Consent**: Written informed consent is required, detailing the test's purpose, potential risks of undetected progression including ESRD, benefits of quantitative assessment, and minimal discomfort from collection.**Procedural Considerations**: The test involves sample processing using spectrophotometry by trained personnel to ensure sterile technique and interpret results within 1-2 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols.**Factors Affecting Result Accuracy**: Incomplete collection, delays beyond stability periods, improper storage conditions, or infection can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.**Clinical Significance**: AER >30 mg/24h indicates microalbuminuria; >300 mg/24h macroalbuminuria, necessitating specialist input.**Specialist Consultation**: Nephrologists or diabetologists should be consulted for management.**Additional Supporting Tests**: Random ACR, eGFR for confirmation.**Test Limitations**: Collection inconvenience; comprehensive approach required.**References**: Indian Journal of Nephrology 2024, Diabetes Kidney Studies India 2023. |
